

ASX Announcement

2 June 2025

ReNerve Expands Product Portfolio Through Strategic Partnership with Berkeley Biologics (Webinar 11:00am AEST, 3rd June 2025)

Two New Tissue-based Product Ranges to Accelerate Growth in 2025

HIGHLIGHTS

- **Strategic Partnership:** ReNerve and Berkeley Biologics join forces to develop and commercialise two complementary tissue-based product ranges.
- **Accelerated Timeline:** First of the two new product ranges targeted for Q3 2025 market launch and the second expected to be launched before year end, with the products now approved in the US.
- **Market Synergy:** New products will be complementary to the existing ReNerve portfolio, used in the same surgical procedures that sometimes require nerve repairs or nerve replacement and sold through ReNerve's existing distribution network to existing surgeon customers.
- **Expanded Offering:** The strategic partnership enhances ReNerve's comprehensive suite of surgical solutions in peripheral nerve injury repairs and related surgeries.
- **Webinar Update:** Dr Julian Chick, ReNerve Director, to discuss the partnership via live webinar and Q&A on Tuesday, 3 June 2025 at 11:00am AEST.

ReNerve Limited (ASX:RNV) ("**ReNerve**" or the "**Company**"), a pioneering medical device company transforming peripheral nerve repair, is pleased to announce a strategic partnership with Berkeley Biologics LLC ("**Berkeley**") to develop and commercialise two new complementary tissue-based product ranges. This collaboration strengthens ReNerve's position in the surgical tissue market and broadens its offerings to existing customers in the peripheral nerve injury ("**PNI**") repair space.

ReNerve Director, Dr Julian Chick, will be providing an overview of the partnership and a Q&A via live webinar on Tuesday 3 June 2025 at 11:00am AEST (Registration: <https://bit.ly/RNV-3-June-2025>).

Over the coming months, the two companies will look to launch the programs for the new product ranges into the US market, with the two product ranges already approved in the US. The products will be produced in the US at Berkeley Biologics' California facility. As part of the partnership, the two companies have entered an initial 5-year supply agreement for the product ranges, with an ability to extend.

The two companies will initially focus on two product ranges: one product range addressing the need for human dermal tissue, deeper layers of the skin often sourced from donors, and the other providing a range of amniotic tissue products, which are known for their regenerative and healing properties. The global dermal and amniotic tissue market is estimated to be worth around USD\$2.7 billion in 2024 and growing at around 12% CAGR¹, with these products used in a range of applications.

These products have application in the medical procedures that ReNerve seeks to address with its current and future NervAlign™ range of nerve repair and nerve replacement products. Accordingly, their sale will be a natural extension of ReNerve's current sales activities, using the same sales network and targeting the same surgeon and hospital customers.

ReNerve plans to launch the first new product line in Q3 2025, with the second reaching market before year-end. These innovative solutions address multiple surgical applications including trauma and wound care, breast reconstruction, foot and ankle procedures, extremity repairs, and orthopaedic and plastic surgeries. The products enable surgeons to incorporate additional tissue grafts when treating nerve injuries, addressing both the damaged nerve and underlying trauma.

Commenting on the new partnership with Berkeley Biologics and the new product ranges, ReNerve Director, Dr Julian Chick, stated: *"The rationale for this partnership is to build-out the product offerings that ReNerve can provide to surgeons, patients and hospitals. The products we are looking to launch this year are used by the existing and new customers for ReNerve's peripheral nerve product range. Surgeons that work on nerve repairs also undertake other types of surgery, where they are required to repair not only damaged nerves. With these two new product lines, the Company can offer surgeons, hospitals and patients a more complete product range for all the tissues that are required for surgery."*

The company will hold a webinar at 11:00am AEST on Tuesday, 3rd of June to discuss this partnership, followed by a brief Q&A.

Register using the QR code, or at <https://bit.ly/RNV-3-June-2025>).



This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick

CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Jane Morgan

Investor & Media Relations
Jane Morgan Management
+61 (0) 405 555 618
info@janemorganmanagement.com.au

¹ MarketWide Research – Dermal and Amniotic tissue market report 2025-2032, Published 2025

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. Recent clinical studies have demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions:

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **NervAlign® Nerve Graft** – Eliminating the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 38% revenue growth in FY24, reaching \$177k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.96 billion in 2024 and is projected to reach \$6.2 billion by 2031.²

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

² Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)

About Berkeley Biologics

Berkeley Biologics is dedicated to restoring health and improving surgical outcomes by developing innovative biologics and wound care products that enhance bone healing and soft tissue regeneration. With a deep commitment to safety, quality, and honoring the gift of donation, our comprehensive portfolio supports a wide range of clinical specialties—including spine, sports medicine, orthopaedics, trauma, dental, and wound care. Our vision remains clear: to be the trusted partner delivering high-quality, life-changing solutions with exceptional value and reliability.